Study of AK146D1 and AK112 for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two experimental drugs, AK146D1 and AK112, for people with advanced non-small cell lung cancer that cannot be removed by surgery or treated with standard chemo-radiation. It aims to find out if this combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced non-small cell lung cancer (stage IIIB/IIIC or IV) that cannot be cured by surgery or standard chemo-radiation.
- You must be in good enough physical condition to be up and about (ECOG score 0 or 1).
- You must have at least one measurable tumor outside the brain.
- You must not have had previous treatment targeting the Trop2 or Nectin4 proteins or topoisomerase I inhibitors.
- You must not have active or untreated brain metastases, unless they are stable after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental drugs (AMT-116 and ivosidan) for patients with advanced lung cancer that cannot be removed by surgery. The study aims to see if this combination can help shrink tumors and improve survival.
This trial tests a new drug called AK146D1 for people with advanced solid tumors that have not responded to standard treatments or no longer work. The goal is to see if it is safe and effective.
This trial tests a new drug called AK112 for people with a certain type of advanced lung cancer that has specific gene changes (like EGFR or ALK) and where previous targeted therapy pills stopped working. It is a phase 2 study, so it helps find out if the drug is safe and effective, possibly offering a new option when standard treatments fail.
This trial tests a new combination of an immunotherapy drug (AK112) with standard chemotherapy as the first treatment for people with a certain type of lung cancer that has spread to the brain. It may help control the cancer by boosting your immune system to fight it, and the study will check how well it works and how safe it is.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This trial tests a new drug, AK112, combined with chemotherapy for people with advanced non-squamous non-small cell lung cancer that has spread to the lining of the lung (malignant pleural effusion). The goal is to see if this combination helps shrink tumors and improve outcomes.
Hear when a new Advanced Non Small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.